Emerging evidence demonstrates that GLP-1 receptor agonists may provide significant benefits for liver health, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and its inflammatory subtype, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH)
2 mg Vial Examples 5 mg Vial Examples These calculations assume 100% net peptide content
Medicare Part D may cover weight loss drugs if they're prescribed to treat another health condition, like diabetes
N Engl J Med 2025;392:777-87.ArticlePubMed 118
Per Joel Bikman, a longtime nutrition executive and the co-founder of a science-based health and wellness company, clever drug manufacturers discovered that by considerably increasing the dosages, these drugs had a powerful effect on weight loss albeit with some alarming side effects, including nausea, vomiting,diarrhea, abdominal pain, rapid heartbeat, vision changes, fainting or dizziness and more